RASAL3 deficient CAR-T cells

RASAL3 deficient CAR-T cells are a genetically engineered form of chimeric antigen receptor (CAR) T cell therapy in which the gene encoding RASAL3, a Ras GTPase-activating protein, is knocked out or suppressed. The rationale for this modification stems from research showing that RASAL3 acts as a negative regulator of T cell function by suppressing Ras signaling and limiting LFA-1 activation, which is important for T cell adhesion and migration[4][5]. By creating CAR-T cells lacking RASAL3, researchers aim to enhance the persistence, migration, and anti-tumor activity of these therapeutic cells. This approach is part of next-generation strategies to improve the efficacy of CAR-T therapies—especially against solid tumors—by overcoming barriers such as poor trafficking to tumor sites and limited survival within the tumor microenvironment[1][2]. These modified CAR-T cells are still experimental and have not yet reached late-stage clinical development.